Fig. 2From: A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancerKaplan–Meier curve for progression-free survival in patients with camrelizumab plus apatinib 500 mg and fuzuloparibBack to article page